Antibodies Therapies against Infectious Diseases
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (30 May 2014) | Viewed by 8482
Special Issue Editor
2. Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK
Interests: rhinovirus; HCMV; HIV; monoclonal antibodies; vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Approximately 30 monoclonal antibodies are currently licensed for use to treat human diseases such as cancer, autoimmune disorders, allergy and transplant rejection. However, just one monoclonal antibody (palivizumab) is licensed that targets an infectious disease pathogen (respiratory syncytial virus, RSV). Nevertheless, several antibodies (approximately 10 of 200) are undergoing preclinical development, or are in clinical trials, for viral infectious diseases. The current Special Issue welcomes contributions from experts in the field that address and review the current state-of-the art technology and developments in the field of antibody therapies against infectious diseases.
Dr. Gary McLean
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- monoclonal antibodies
- infectious diseases
- prophylactic
- therapeutic
- clinical trial
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
